US ERA ARCHIVE DOCUMENT

ISSUES SUBGROUP (Q&A FORMAT)

PPDC Work Group on 21st Century
Toxicology/New Integrated Testing
Strategies

ISSUES SUBGROUP (Q&A FORMAT)

- Formed June 2009
- Members
 - Kristie Sullivan
 - James Roberts
 - Erik Janus
- CHARGE: Capture salient stakeholder issues related to new testing methods and strategies and present them in Q&A format

ISSUES SUBGROUP (Q&A FORMAT)

- Final product: Tool for EPA
 - Education
 - Research
 - Communication & Outreach
- Final product: document
 - Questions
 - "Points to consider" when creating response
 - Some questions may not be answerable yet

PROCESS-Q generation

- Brainstorming
- Quizzing constituents
- Listening
 - Full PPDC meetings
 - Workgroup meetings

PROCESS-Developing list

- Comments
 - Workgroup
 - Constituents
 - EPA
- Parity and Reorganization
- Check for duplication with web site
- Development of "points to consider" for EPA to use in formulating answers

STAKEHOLDER ISSUES (Q&A FORMAT)

- General questions
 - What is the timeline for this process?
- Technical questions
 - How will this new paradigm take human variability into account?
- Major themes
 - Benefits/drawbacks of paradigm shift
 - Maintaining environmental and health protection

WHAT?

What changes are taking place?

WHY?

 Why is EPA, and OPP specifically, making efforts to implement these changes in toxicity testing and assessment?

WHEN?

- When does OPP plan to transition from the use of current methods to the use of new tools and ultimately implement the NRC Vision "paradigm shift"?
 - Suggest timeline linked with other workgroup products, like the Tools or Metrics Matrices
 - General view rather than hard and fast deadlines

HOW will these changes affect OPP's mission?

- How will the EPA ensure that the current level of protection of human health and the environment is maintained or enhanced?
- How will decision-making be improved by the use of molecular information?
- How will the new toxicity testing paradigm increase the efficiency of the pesticide regulation process?
 What are the expected resource savings for both regulators and the regulated community?

- How will this initiative be followed over time and upgraded and improved upon?
- How will EPA recognize the limitations and uncertainties associated with the use of the newer non-animal testing methods and take them into account during the risk assessment process?
 - What tools/checks are in place?

WHO?

 What are the opportunities for public and other stakeholder input? How can the public, academic, business and other federal agencies become engaged? How transparent will this process be?

Stakeholder Issues-Technical

- How can in vitro testing specifically predict the potential of a substance to cause adverse effects at higher levels of biological complexity (i.e. organ, system and organism level)?
 - Context: endpoints such as developmental tox
 - Translating data into risk management
- How will inter-individual variations in the human population (i.e. genetic and metabolic differences) be captured by in vitro and in silico methods?

Stakeholder Issues-Technical

 Sometimes during the implementation of new technologies or advances in science, methods that were originally considered to be replacements for current technologies become, for a number of reasons, additional requirements. What specific steps and actions is OPP and/or EPA taking to ensure the regulatory acceptance of newer methods?

Stakeholder Issues-Technical

 How will this new testing and assessment paradigm affect our ability to identify health outcomes from chemicals in worker or public populations? Will EPA have a way to identify chemicals that may be contributing to an increased disease burden in the population?

BACK TO YOU

- What have we missed?
- Check out the handout and web site and tell us what you DO and DON'T see!

http://www.epa.gov/pesticides/science/ testing-assessment.html